Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences

– Acquisition of next-generation Kv7 channel activators for target indications including epilepsy, pain disorders and affective disorders – BHV-7000 is the lead asset from Kv7 channel platform and is potentially a best-in-class potassium channel activator with a profile suggestive for … Continued

Top Fintech Trends to Watch in 2022

NEW YORK, January 24, 2022 ( – Few industries have been as exciting and disruptive in recent years as the burgeoning fintech space. Between the evolution of digital payment methods and checkout options, and increased access to alternative investment opportunities for … Continued

Knopp Biosciences: Dexpramipexole targets eosinophilic inflammation

Knopp Biosciences’ investigational, first-in-class drug, dexpramipexole, holds promise for patients with asthma and eosinophil-associated diseases. Asthma affects more than 300 million people worldwide, and is the most common noncommunicable disease among children. No cure exists for chronic asthma; most patients … Continued

Yieldstreet Unveils High-End-Art Fund for Smaller Investors

Investment in YieldStreet’s art fund for smaller investors starts at $10,000 with returns aimed at 15% to 17%. Asset-investment firm Yieldstreet on Friday launched the Art Equity Platform, which is a series of funds that enable retail investors to buy into a … Continued

Basalt to Acquire Xpress Natural Gas

NEW YORK–(BUSINESS WIRE)–Feb 1, 2021– Basalt Infrastructure Partners LLC (“Basalt”) announced today that the third flagship Basalt fund (“Basalt III”) has entered into a definitive agreement to acquire Xpress Natural Gas (“XNG” or the “Company”). XNG is a fully integrated … Continued